Skip to main content
. 2022 Nov 7;12(1):23–36. doi: 10.12997/jla.2023.12.1.23

Fig. 1. Therapeutic approaches targeting apoC-III and ANGPTL3.

Fig. 1

ASO for the inactivation of apoC-III (volanesorsen and olezarsen) and ANGPTL3 (vupanorsen), and a monoclonal antibody (evinacumab) to ANGPTL3 have been developed.

ASO, antisense oligonucleotide; apoC-III, apolipoprotein C-III; ANGPTL3, angiopoietin-like protein 3.